InnovationDiscover our research
Our commitment to research, development and the production of innovative products.
Globally, the Dompé group is active in primary care, prescription therapies, over the counter (OTC) medicines, dietary supplements, medical devices and cosmetics.
We are committed to finding innovative solutions for the treatment of rare diseases with high unmet need.
In the US, Dompé’s recombinant human Nerve Growth Factor(rhNGF)-based therapy, cenegermin-bkbj was reviewed under Breakthrough Therapy and Priority Review designation by the Food and Drug Administration (FDA) and approved in August 2018 for the treatment of Neurotrophic Keratitis.
Dompé farmaceutici was founded in 1940, with its roots in 19th century pharmaceutical science.
Every year, the Dompé group reinvests 15% of our annual profit in Research & Development (R&D).
Part of a global network of over 300 partner centers to support our research.
Research, development and production contributing to innovation
Our hub in L’Aquila is a center for both manufacturing and drug discovery, including small molecules and biotech therapies from early stage through clinical development and commercialization.Discover our production hub
Manufacturing in L'Aquilla Italy
8 Production lines
manufactured packages per year globally
Contract Development and Manufacturing Organization for synthesis and biotech